Ildong’s Samion gets momentum

Ildong Pharm's Samion (nicergolin), cererovascular medicine, has fared well since the middle period of last year thanks to the company’s intensive marketing campaigns.

Samion has garnered more than 10 billion won in revenue, while most of nicergolin drug makers discontinued the production due to sluggish sales.

Experts say that Samion will be highlighted as a substitute drug of ginkgo bil...